Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma. (7th April 2016)

• Record Type: Journal Article
• Authors: Barth, Matthew J.; Chu, Yaya; Hanley, Patrick J.; Cairo, Mitchell S.
• Other Names: Cairo Mitch guestEditor.; Pinkerton Ross guestEditor.
• Is Part Of: British journal of haematology. Volume 173:Number 4(2016)
• Page Start: 597
• Page End: 616
• Publication Date: 2016-04-07
• Subjects: Immunotherapy -- monoclonal antibody -- chimeric antigen receptor -- latent membrane protein -- cytotoxic T‐lymphocyte; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.14078
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: With the introduction of the anti‐CD20 monoclonal antibody rituximab, B‐cell non‐Hodgkin lymphoma was the first malignancy successfully treated with an immunotherapeutic agent. Since then, numerous advances have expanded the repertoire of immunotherapeutic agents available for the treatment of a variety of malignancies, including many lymphoma subtypes. These include the introduction of monoclonal antibodies targeting a variety of cell surface proteins, including the successful targeting of immunoregulatory checkpoint receptors present on T‐cells or tumour cells. Additionally, cellular immunotherapeutic approaches utilize T‐ or Natural Killer‐cells generated with chimeric antigen receptors against cell surface proteins or Epstein–Barr virus‐associated latent membrane proteins. The following review describes the current state of immunotherapy for non‐Hodgkin lymphoma including a summary of currently available data and promising agents currently in clinical development with future promise in the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma.